Civic AI
Procurement intelligence
Federal contract award
TO TITLE: TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · Department of Health and Human Services
- Value
- $1,249,115
- Start
- Jun 26, 2023
- End
- Oct 25, 2026
- Action date
- Mar 9, 2026
- PIID
- 75N91023F00002
- Status
- active
- NAICS
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- Place of performance
- HOUSTON, TX
- Award type
- DELIVERY ORDER
Description
TO TITLE: TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS
Need modifications, related awards, and vendor peers? Open the full award workspace.